ABSTRACT: Background. The purpose of this study was to establish the efficacy and toxicities of concurrent bevacizumab and docetaxel with radiation for locally advanced head and neck squamous cell carcinoma (HNSCC). Methods. Patients with previously untreated HNSCC received standard daily radiotherapy (RT) with concurrent weekly docetaxel (20 mg/m 2 ) and biweekly bevacizumab (5 mg/kg). Biweekly bevacizumab was then continued for up to 1 year after RT. The primary objective was progression-free survival (PFS). Secondary objectives included overall survival (OS), patterns of failure, and toxicities of treatment. Results. Thirty patients were recruited. With median follow-up of 38 months, the 3-year PFS, OS, locoregional recurrence-free survival, and distant metastasis-free survival was 61.7%, 68.2%, 84.5%, and 80.5%, respectively. The most common local toxicities were mucositis and dermatitis. Two patients developed hemorrhage. There was no grade 5 toxicity. Conclusion. The combination of bevacizumab, docetaxel, and RT is tolerable and effective in HNSCC. This regimen is worthy of further study in appropriate subset of patients receiving chemoradiation therapy.
INTRODUCTION
Head and neck cancer is the eighth most common cancer in the United States. 1 For locally advanced HNSCC, concurrent chemoradiotherapy (CRT) is the standard treatment established with multiple randomized trials. [2] [3] [4] The survival benefit of CRT in locally advanced head and neck squamous cell carcinoma (HNSCC) has been confirmed by meta-analyses, which revealed a 19% reduction in mortality and an absolute survival benefit of 8% at 5 years when chemotherapy was administered concurrently with radiation. 5, 6 Despite incremental improvements in locoregional control and survival in patients with HNSCC treated with CRT, a substantial fraction of patients suffer persistent or recurrent diseases. Combining novel agents with radiation therapy therefore remains of great interest to further improving the treatment outcomes of HNSCC.
Cisplatin is the most commonly used chemotherapeutic agent given concurrently with radiation. However, introduction of additional effective radiosensitizing agents is urgently needed. A significant percentage of patients appropriate for definitive concurrent CRT are not candidates for cisplatin-based treatment. Furthermore, recent data have emerged that cisplatin might not be the most optimal cytotoxic radiosensitizing agent when addition of novel targeted agents to concurrent CRT is evaluated.
Radiation Therapy Oncology Group (RTOG) 0234 is a phase II randomized clinical trial evaluating postoperative radiation plus concurrent docetaxel and cetuximab versus postoperative radiation plus cisplatin and cetuximab for high-risk HNSCC after surgery. The results showed an impressive improvement in overall survival (OS) and disease-free survival of the docetaxel arm compared to the cisplatin arm (79% vs 69% and 66% vs 57%, respectively. 7 These results are pointing to the possibility that a non-cisplatin-based regimen CRT should be explored for further development of novel targeted agents and led to a recently opened phase III randomized RTOG trial, RTOG 1216, which compares postoperative radiation with concurrent cisplatin versus docetaxel versus docetaxel and cetuximab for patients with high-risk HNSCC.
Vascular endothelial growth factor (VEGF) is one of the most important regulators of angiogenesis. Upregulation of VEGF has been found in many HNSCC and was shown to be associated with radioresistance and poor prognosis. 8, 9 Bevacizumab is a recombinant humanized anti-VEGF monoclonal antibody and has been shown in preclinical models to be a radiation sensitizer and can enhance the antitumor efficacy of radiation and chemotherapeutic agents. [10] [11] [12] Our group has extensive experience in studying the efficacy and toxicities of targeted therapies added to a docetaxel-based CRT both in phase I and phase II settings. 13, 14 Initial selection of docetaxel was based on its documented potent radiosensitizing effects and favorable toxicity profile when compared to cisplatin. We developed the first protocol combining radiotherapy (RT) with the doublet of docetaxel/bevacizumab in the effort to identify a non-cisplatin concurrent CRT regimen. Herein, we report the results of this phase II clinical trial.
MATERIALS AND METHODS
This was a nonrandomized open-label phase II study opened in University Hospitals Case Medical Center and University of Pittsburgh Medical Center (UPMC). The study was approved by the Institutional Review Boards of Case Comprehensive Cancer Center and UPMC. All patients provided Institutional Review Board-approved written informed consent before study enrollment.
Patient eligibility and baseline assessment
Eligible patients had histologically confirmed previously untreated stage III to IVA/B HNSCC without distant metastatic disease. Patients were evaluated by a multidisciplinary team that included otolaryngologists, medical oncologists, and radiation oncologists. Each case was presented at a multidisciplinary tumor board for consensus treatment recommendations and to assess the appropriateness for a clinical trial. Pretreatment evaluation included history and physical examination, triple endoscopy, and radiographic imaging of the head, neck, and chest before enrollment to the study. All patients underwent dental evaluation before treatment. If dental extractions were required, at least 7 days of healing was required before initiation of radiation. All patients were required to have an Eastern Cooperative Oncology Group performance status of 0 to 1 and adequate bone marrow, renal, and hepatic functions. Percutaneous gastrostomy tubes were placed in the majority of patients (26 of 30) before the start of radiation therapy unless refused by the patient per institutional practice.
Patients with squamous cell carcinoma of the salivary gland and paranasal carcinomas were excluded from the study. Also excluded were patients with grade 2 preexisting peripheral neuropathy, history of allergic reactions to the chemotherapeutic agents, and uncontrolled intercurrent diseases, as well as HIV-positive patients. With respect to bevacizumab specific concerns, patients with a history of stroke or myocardial infarction within 6 months, blood pressure >150/100, urine protein:creatinine ratio 1.0, New York Heart Association grade II or greater congestive heart failure, unstable angina, or evidence of bleeding diathesis or coagulopathy, major surgery, or significant traumatic injuries within 28 days before day 0 of treatment were also excluded from this study. Those who had close proximity or involvement of major blood vessels by the tumor or nodes were also excluded.
Protocol treatment
The treatment schema is summarized in Figure 1 .
Chemotherapy
Treatment was administered on an out-patient basis. Bevacizumab was administered 5 mg/kg intravenously over a 90-minute infusion once every 2 weeks during the course of radiation and up to 1 year after the completion of RT. If neck dissection was performed, bevacizumab was stopped for at least 8 weeks before surgery and then reinitiated at a minimum of 4 weeks after neck dissection. Docetaxel was administered intravenously once per week during the course of radiation. A dose of 20 mg/m 2 was given over a 60-minute infusion either alone or after bevacizumab administration. Premedication included dexamethasone 4 mg orally daily for 3 doses 24 hours before docetaxel, benadryl 50 mg, and ranitidine 50 mg intravenously 30 minutes before docetaxel administration. Antiemetic agents were administered 30 minutes before docetaxel.
Radiotherapy
Concurrent with chemotherapy, RT was delivered using standard once-daily fractionation, 5 days a week (excluding weekends and holidays). Both conventional radiation technique and intensity-modulated radiation therapy were allowed. For conventional technique, the primary region and adjacent lymphatic areas were treated to 39.6 Gy after which appropriate off-cord field reductions were made. The posterior neck was then treated to a total dose of 50.4 Gy. The off-cord field was given an additional 10.8 Gy. Subsequently, the primary tumor and involved nodes received an additional 19.8 Gy utilizing a conformal technique. The total planned dose to the primary tumor and the involved nodes was 70.2 Gy. The supraclavicular area received 50.4 Gy in 28 fractions of 1.8 Gy. For patients treated with intensity-modulated radiation therapy, the primary tumor and involved nodes were treated to 70 Gy, the high-risk lymphatic regions to 63 Gy, and the intermediate risk areas to 56 Gy. All these volumes were treated simultaneously using dose painting in 35 fractions.
Study evaluation and assessment of response
Adverse events were evaluated weekly using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3. CT of the head, neck, and chest (and optional fluorodeoxyglucose positron emission tomography scans) were obtained 8 to 12 weeks after completion of concurrent CRT, and every 2 months thereafter during adjuvant treatment with bevacizumab up to 1 year, and at the end of the study. Salvage surgery was performed for patients with persistent or recurrent disease at least 8 weeks from their last infusion of bevacizumab. Patients were seen monthly if they remained on adjuvant bevacizumab for up to 1 year, and every 3 months thereafter.
Study objectives and statistical considerations
The primary purpose of this study was to determine the 3-year progression-free survival (PFS) of patients with locally advanced HNSCC treated with the combination of decetaxel, bevacizumab, and concurrent RT. Secondary endpoints included objective response rate, locoregional control rate, duration of response, patterns of failure, and OS. Based on phase II/III clinical trials of chemoradiation in the treatment of locally advanced HNSCC at the time this study was designed, it was estimated that the probability of disease PFS at 3 years after treatment was about 50%. To detect an improvement in the 3-year PFS rate from 50% to 75%, the study required 27 patients (type I error of 0.05, a power of 80%, and a follow-up period of 24 months after enrollment of the last patient).
Time to PFS was calculated from the start of treatment to the date of disease progression or the date of death, whichever came first, and censored at the date of last follow-up for those alive and without disease progression. OS was calculated from the start of treatment to the date of death and censored at the date of last follow-up for survivors. Distant metastases-free survival was calculated from the start of treatment to the date of distant metastases and censored at the date of last follow-up for those without metastases. Locoregional failure-free survival was calculated from the start of treatment to the date of locoregional failure and censored at the date of last follow-up for those without locoregional failure. Probability of survival was estimated by Kaplan-Meier method and the difference of survival between groups was examined by log-rank test. All tests were 2-sided and p values .05 were considered statistically significant.
RESULTS

Patient characteristics
From December 2005 through September 2008, 30 patients were enrolled on this study (27 from University Hospitals Case Medical Center and 3 from UPMC). Patient characteristics are summarized in Table 1 . The median age was 55.5 years (range, 43-73 years) and the majority of patients were men (87%). The primary site included 20 oropharynx, 7 larynx, 2 hypopharynx, and 1 oral cavity (retromolar trigone). The majority of patients had stage IVA/B disease (80%). Primary T classification was split between T1/T2 tumors and T3/T4 tumors at 47% and 53%, respectively. The majority of patients had advanced nodal disease (N2/N3; 73%).
Human papillomavirus (HPV) status was determined retrospectively on 18 patients that had tissue available for further testing. Of these patients, 12 were HPV-positive, all with oropharynx primary with the exception of 1 patient with supraglottic laryngeal cancer.
Treatment delivery and toxicity
Of the 30 patients enrolled on this study, 28 completed a full course of RT. One patient developed aspiration pneumonia during RT requiring prolonged hospitalization after he had received 59.4 Gy. Because of the prolonged treatment break and the patient's general condition, the treatment was discontinued. A second patient experienced a grade 4 oropharyngeal hemorrhage at 27 Gy requiring hospital admission and the RT was discontinued at that time.
Median dose intensities of planned chemotherapy were 20 mg/m2/qwk, 3 8 doses for docetaxel, and 5 mg/kg/ qow, 3 4 doses for bevacizumab during concurrent CRT. Only 10 patients did not receive any adjuvant bevacizumab treatments. The remaining 20 patients received a median of 8 treatments (range, 2-22). Selected toxicities of CRT are shown in Table 2 . The most common nonhematologic grade 3 or higher toxicity was dysphagia, which was likely related to radiationinduced mucositis. There was no grade 3 or higher leukopenia, however, a substantial number of patients had grade 3 lymphopenia (80%). There were 2 episodes of grade 4 bleeding seen in the study. One patient experienced an oropharyngeal hemorrhage from the lingual artery during chemoradiation, which occurred in the radiation field. A second patient experienced hemorrhagic cholecystitis requiring a cholecystectomy. One patient developed a deep vein thrombosis requiring anticoagulation. There were no grade 5 toxicities.
Regarding late toxicity, 1 patient experienced radiation necrosis of the larynx requiring total laryngectomy. Pharyngoesophageal stenosis requiring esophageal dilatation (grade 3 dysphagia) was observed in 23% of the patients.
Survival and patterns of failure
The median follow-up was 38 months (range, 2-64 months) for the whole group. At last follow-up, 21 patients were alive without evidence of disease progression. The 3-year PFS was 61.7% (95% confidence interval 'CI' 5 41.5% to 75.7%). Of those completing chemoradiation therapy, the 3-year PFS was 66.2% (95% CI 5 45% to 80.8%). The median PFS was not reached at the last follow-up (>64 months; Figure 2 ). The 3-year OS was 68.2% (95% CI 5 47.5% to 82.1%). Of those completing CRT, the 3-year OS was 73.2% (95% CI 5 51.7% to 86.3%). Again, the median OS was not reached at last follow-up (>64 months; Figure 3 ).
For the analysis of patterns of failure, information was available on 27 patients. There were 4 locoregional failures. One patient had local recurrence only, 2 with both local and regional recurrences, and 1 with local and distant recurrences. The 3-year locoregional failure-free survival was 84.5% (95% CI 5 63.7% to 93.9%; Figure 4 ). All local recurrences occurred during the first 2 years of follow-up. The patient who had local recurrence only underwent a salvage laryngectomy and remained alive with no evidence of disease at the last follow-up. The patients who had both local and regional recurrences underwent salvage surgery and postoperative reirradiation, but both succumbed to the disease later.
There were 6 patients who developed distant metastasis, all had lung metastases. Five of these patients had distant metastases as the first and only failure. The 3-year distant metastases-free survival was 80.5% (95% CI 5 59% to 91.5%; Figure 5 ).
DISCUSSION
We reported here a nonrandomized phase II clinical trial using a novel combination of concurrent bevacizumab, docetaxel, and radiation in the management of locally advanced HNSCC. There are 4 other studies that have been published recently combining bevacizumab and other chemotherapeutic agent(s) with radiation in HNSCC. [15] [16] [17] [18] Salama et al 15 in a phase II randomized trial compared 5-fluoruracil, hydroxyurea and twice-daily RT with or without bevacizumab (FHX vs BFHX). Fury et al 16 combined bevacizumab with standard concurrent cisplatin and radiation. Hainsworth et al 17 combined bevacizumab, erlotinib, paclitaxel, and radiation. In their nonrandomized phase II trial, patients were treated with 2 cycles of neoadjuvant chemotherapy with bevacizumab, carboplatin, paclitaxel, and 5-fluoruracil before concurrent CRT. Yoo et al 18 combined bevacizumab, erlotinib, cisplatin, and radiation. Radiation treatment was given twice daily at 1.25 Gy per fraction with a 6-hour interfraction interval and a planned 1 week break during week 4. Our study is the first evaluating the combination of bevacizumab and docetaxel administered concurrently with RT. In the setting of emerging data derived from RTOG 0234 showing postoperative radiation plus docetaxel plus cetuximab resulted in clinically meaningful improvement in OS and disease-free survival when compared to radiation plus cisplatin plus cetuximab for highrisk HNSCC. 7 The need to evaluate the efficacy of bevacizumab added to RT and docetaxel backbone is easily understood and justified.
This trial also provides valuable data on the ongoing discussion of the optimal docetaxel weekly dose given concurrently with radiation. In this trial, docetaxel administered at a weekly dose of 20 mg/m 2 during concurrent RT was effective and well tolerated. Our group has also completed phase I and II studies combining radiation, docetaxel, and the anti-epidermal growth factor receptor tyrosine kinase inhibitor erlotinib and has demonstrated that docetaxel at 20 mg/m 2 /week is well tolerated in combination with erlotinib and radiation. 12, 13 It is of interest to note that a lower docetaxel dose (15 mg/m2/week) was selected in the phase III RTOG 1216 clinical trial. This trial also raises the question of the appropriate dose of bevacizumab. Among the 5 trials, this is the only one that bevacizumab at 5 mg/kg administered every 2 weeks was used, which is half of the dose used in the other 4 trials. Although there are no definitive data for the appropriate dose in combination with RT, both doses are approved to be used in combination with various cytotoxic regimens. 18 We decided to use the same dose intensity (5 mg/kg administered every 2 weeks) used in the first in humans clinical trial evaluating the bevacizumab 19 effects in combination with radiation and cytotoxic chemotherapy. 20 The role of adjuvant treatment and its potential duration after definitive concurrent CRT is an area of active clinical research. Use of bevacizumab in the adjuvant setting to slow down metastasis and improve response to treatment is appealing and needs to be addressed in the clinical setting. 21 However, planned administration of adjuvant bevacizumab was only included in the trial by Fury et al 16 (6 months of maintenance treatment) and in our trial (12 months of maintenance treatment). However, data on the feasibility and tolerability of adjuvant bevacizumab are only available from this trial, as maintenance treatment was discontinued in an amendment after a grade 4 pulmonary hemorrhage event in patient 1 during maintenance treatment. 16 The major local side effects noted in our trial were mucositis and dermatitis. These are consistent with other reports as well as those reported in clinical trials using standard concurrent chemotherapy and radiation in HNSCC. [2] [3] [4] 22, 23 This suggests that bevacizumab did not increase acute local toxicities of chemoradiation. The grade 3 dysphagia in our trial might be overrated. We routinely placed a percutaneous endoscopic gastrostomy tube before treatment and the patients might tend to use tube feeding earlier in the treatment course, which is graded as grade 3 toxicity in Common Terminology Criteria for Adverse Events. There was no grade 5 toxicity in our patients. in their trial. Again, this is consistent with about 4% of treatment-related deaths reported in combined CRT in locally advanced HNSCC. [2] [3] [4] 24 After careful selection of 30 patients treated in this trial, 2 developed hemorrhage, 1 within the radiation field and the other outside the radiation field in the abdomen, which does not point to an unexpected toxicity profile of the combination regimen. Fury et al 16 also reported 1 patient with grade 4 pulmonary hemorrhage that occurred during the maintenance bevacizumab treatment after the completion of CRT. Later, they amended the protocol and eliminated the maintenance bevacizumab treatment. Hemorrhage was not reported in 3 other published studies combining bevacizumab and radiation. In a study 25 using bevacizumab in combination with carboplatin and paclitaxel in previously untreated locally advanced and metastatic non-small cell lung cancer (without radiation), 6 patients experienced major life-threatening bleeding (hemoptysis or hematemesis). They reported that life-threatening bleeding was associated with squamous cell histology, tumor necrosis and cavitations, and disease location close to major blood vessels. Therefore, extreme precaution is needed with strict selection criteria and early detection of any bleeding signs and symptoms when using bevacizumab. Table 3 summarizes the treatment outcomes of published clinical trials in the combination of bevacizumab and CRT in locally advanced HNSCC. In our study, a good locoregional control was obtained. For those who completed radiation treatment, only 4 patients developed locoregional recurrences, 1 of them also with distant metastasis. However, there was a high distant metastasis rate with 3-year distant metastases-free survival of only 80.5%, possibly because of a large portion of our patients with high nodal stages (22 of 30 patients with N2/3 disease). As a result, the PFS, which was the primary endpoint of the study, did not meet the expected efficacy (ie, 3-year PFS of 75%).
Salama et al 15 terminated their randomized phase II study early because of an unexpected high locoregional recurrence in the bevacizumab arm. After 26 patients entered the study, 4 of 5 T4 patients on the BFHX arm had locoregional disease progression versus zero of 2 patients on the FHX arm. They reported 2-year locoregional control was 67% in the BFHX arm and 100% in the FHX arm, and 2-year PFS was 59% in the BFHX arm versus 89% in the FHX arm. For patients treated in the BFHX arm, the doses of 5-fluoruracil and hydroxyurea had to been reduced compared to their standard doses in the FHX regimen, which was required because of elevation of hepatic enzymes. These dose modifications may cause reduction of the radiosensitizing effect of the BFHX regimen. 23 is a randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for locally advanced HNSCC. An analysis of the 895 patients who entered the trial with a median follow-up of 2.4 years for surviving patients, 2-year PFS was 63% vs 64% (with cetuximab vs without) and 2-year OS was 83% vs 80% (with cetuximab vs without), both without significant differences. Both Fury et al 16 and Yoo et al 18 reported better PFS and OS than the RTOG experience with cisplatin and radiation in locally advanced HNSCC. However, these were single institutional studies with a limited patient sample. Multiinstitutional randomized studies with larger patient sample are needed to confirm these findings.
Although our study did not meet the primary prespecified 3-year PFS of 75%, it is well recognized that patient selection and disease heterogeneity can significantly influence outcomes. Our results do not seem greatly different from RT/cisplatin as reported in RTOG 0129 and RTOG 0522. This regimen seems to be worthy of further study for the appropriate selected subgroup of patients, especially for those who are not candidates for cisplatin administration. Abbreviations: LRFFS, locoregional failure free survival; PFS, progression-free survival; OS, overall survival; 5-FU, 5-fluorouracil.
